Sunday, July 13, 2014





Bluebird Bio shares rocket higher in trading debut


June 19. 2013 11:39AM
Associated Press

Story Tools
PrintPrint | E-MailEMail | SaveSave | Hear Generate QR Code QR
Send to Kindle


(AP) Shares of gene therapy developer Bluebird Bio Inc. are surging in their trading debut.


Its shares climbed $9.15, or 53.8 percent, to $26.15 in morning trading Wednesday after trading as high as $27 earlier in the session.


The company's initial public offering of 5.94 million shares had been priced Tuesday at $17 per share, above its initial expectations of $14 to $16 per share.


That raised $101 million before underwriting costs and other expenses.


Bluebird is developing gene therapies for severe genetic and very rare diseases.


The underwriters of the IPO have the option to buy another 891,000 shares of the Cambridge, Mass., company over the next month.


Associated Press


Comments
comments powered by Disqus Commenting Guidelines
Poll
Mortgage Minute


Search for New & Used Cars

Make 
Model
 
Used New All
 

Search Times Leader Classifieds to find just the home you want!

Search Times Leader Classifieds to find just what you need!

Search Pet Classifieds
Dogs Cats Other Animals



Social Media/RSS
Times Leader on Twitter
Times Leader on Youtube
Times Leader on Google+
The Times Leader on Tumblr
The Times Leader on Pinterest
Times Leader RSS Feeds